AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18686769 — intervention group
Group type: COMPARATOR
Intervention: Scaling/root planing plus control gel application (polydimethylsiloxane 13%)
Number of subjects: 20
Study 15625365 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose (SD) ifosfamide (1.5 g/m2/d, days 1 through 4) plus doxorubicin (60 mg/m2)
Number of subjects: 79
Study 15625365 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose (HD) ifosfamide (3.0 g/m2, days 1 through 4) plus doxorubicin (60 mg/m2)
Number of subjects: 79
Study 12461418 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 229
Study 12461418 — intervention group
Group type: COMPARATOR
Intervention: Control (no hydroxyurea)
Number of subjects: 229
Study 10325738 — intervention group
Group type: EXPERIMENTAL
Intervention: Picolax (sodium picosulphate 10 mg/sachet with magnesium citrate) and clear fluids
Number of subjects: 66
Study 10325738 — intervention group
Group type: COMPARATOR
Intervention: Bisacodyl tablets with an unrestricted diet and a phosphate enema
Number of subjects: 66
Study 8946103 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 3% sodium trimetaphosphate (TMP)
Number of subjects: 2500
Study 8946103 — intervention group
Group type: COMPARATOR
Intervention: Control toothpaste containing no caries‐preventive agent
Number of subjects: 2500
Study 1508343 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-fentanyl
Number of subjects: 0
Study 1508343 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane-fentanyl
Number of subjects: 0
Study 1508343 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 6703927 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (100 mg ASA + 75 mg DPM, t.d.s.)
Number of subjects: 17
Study 6703927 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aspirin (300 mg ASA + 75 mg DPM, t.d.s.)
Number of subjects: 17
Study 6703927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 30775611 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Lifestyle Balance™ (GLB-TBI)
Number of subjects: 66
Study 30775611 — intervention group
Group type: COMPARATOR
Intervention: Attention control educational support group
Number of subjects: 66
Study 29719379 — intervention group
Group type: EXPERIMENTAL
Intervention: Orodispersible film (ODF) of tadalafil (20 mg)
Number of subjects: 40
Study 29719379 — intervention group
Group type: COMPARATOR
Intervention: Film-coated tablet (FCT) of tadalafil (20 mg)
Number of subjects: 40
Study 27050538 — intervention group
Group type: EXPERIMENTAL
Intervention: Coflex Interlaminar Stabilization
Number of subjects: 290
Study 27050538 — intervention group
Group type: COMPARATOR
Intervention: Fusion
Number of subjects: 290
Study 25017558 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-day T-Care intervention delivered by a psychiatric nurse practitioner (NP)
Number of subjects: 20
Study 22353022 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg weekly for 96 weeks
Number of subjects: 44
Study 22353022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 19965682 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 614
Study 19965682 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 614
Study 19965682 — intervention group
Group type: EXPERIMENTAL
Intervention: Major surgery
Number of subjects: 614
Study 19965682 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor surgery
Number of subjects: 614
Study 17223655 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular (90)Y distribution mainly diffuse
Number of subjects: 69
Study 17223655 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular (90)Y distribution mainly focal
Number of subjects: 69
Study 17223655 — intervention group
Group type: EXPERIMENTAL
Intervention: (90)Y leakage to liver
Number of subjects: 69
Study 17223655 — intervention group
Group type: EXPERIMENTAL
Intervention: (90)Y leakage to spleen
Number of subjects: 69
Study 17223655 — intervention group
Group type: COMPARATOR
Intervention: Diffuse intra-articular (90)Y distribution
Number of subjects: 69
Study 16282540 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic rehabilitation program with additional arm, leg, or air splint therapy
Number of subjects: 101
Study 16282540 — intervention group
Group type: EXPERIMENTAL
Intervention: Time itself
Number of subjects: 101
Study 11995883 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical posterior approach (Group 1)
Number of subjects: 183
Study 11995883 — intervention group
Group type: COMPARATOR
Intervention: Modified posterior approach (Group 2)
Number of subjects: 183
Study 9481631 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-fortified bread providing 2 mg/kg/day elemental zinc acetate for 90 days
Number of subjects: 24
Study 9481631 — intervention group
Group type: COMPARATOR
Intervention: Control group (same quality bread with no zinc fortification)
Number of subjects: 24
Study 7874898 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg four times daily added to standard enteral nutrition feeding protocol
Number of subjects: 21
Study 7874898 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral nutrition feeding protocol without cisapride
Number of subjects: 21
Study 7874898 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 21
Study 2404046 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg once a day)
Number of subjects: 772
Study 2404046 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg three times a day)
Number of subjects: 772
Study 2404046 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole (325 mg and 75 mg together three times a day)
Number of subjects: 772
Study 2404046 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfinpyrazone (267 mg three times a day)
Number of subjects: 772
Study 2404046 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nonaspirin group)
Number of subjects: 772
Study 2404046 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin group
Number of subjects: 772
Study 369471 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of DTgammaE zinc phosphate daily intramuscularly for about seven days (study 1)
Number of subjects: 14
Study 369471 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of nonlasting DTgammaE in saline daily intramuscularly for eight days (study 2)
Number of subjects: 14
Study 369471 — intervention group
Group type: COMPARATOR
Intervention: Neuroleptic therapy maintained in six patients and drug-free in two patients (study 2)
Number of subjects: 14
Study 31315417 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 248
Study 27853913 — intervention group
Group type: EXPERIMENTAL
Intervention: Preimplantation genetic screening (PGS) with double embryo transfer (DET)
Number of subjects: 398
Study 27853913 — intervention group
Group type: EXPERIMENTAL
Intervention: Preimplantation genetic screening (PGS) with single embryo transfer (SET)
Number of subjects: 398
Study 27853913 — intervention group
Group type: COMPARATOR
Intervention: Non-PGS embryo transfers
Number of subjects: 398
Study 27853913 — intervention group
Group type: EXPERIMENTAL
Intervention: Preimplantation genetic screening (PGS)
Number of subjects: 398
Study 25886384 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined nutraceutical containing berberine, chlorogenic acid and tocotrienols
Number of subjects: 40
Study 25886384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23644921 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate postpartum curettage
Number of subjects: 420
Study 23644921 — intervention group
Group type: COMPARATOR
Intervention: Control group (no curettage)
Number of subjects: 420
Study 21639638 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic computer‐tailored print intervention
Number of subjects: 1971
Study 21639638 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmentally computer‐tailored print intervention
Number of subjects: 1971
Study 21639638 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 1971
Study 19894301 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) combined with standard rehabilitation
Number of subjects: 55
Study 19894301 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation
Number of subjects: 55
Study 16996599 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebound tonometer (RBT)
Number of subjects: 90
Study 16996599 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic contour tonometer (DCT)
Number of subjects: 90
Study 16996599 — intervention group
Group type: COMPARATOR
Intervention: Goldmann applanation tonometer (GAT)
Number of subjects: 90
Study 16996599 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebound tonometer (RBT) and Dynamic contour tonometer (DCT)
Number of subjects: 90
Study 15207200 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical intervention in a monitoring programme for type-2 diabetics
Number of subjects: 126
Study 15207200 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 126
Study 11132738 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt group (supine with a 30 degree leftward tilt)
Number of subjects: 293
Study 11132738 — intervention group
Group type: COMPARATOR
Intervention: Lateral group (left lateral decubitus position)
Number of subjects: 293
Study 11132738 — intervention group
Group type: COMPARATOR
Intervention: Lateral group
Number of subjects: 293
Study 11132738 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt group
Number of subjects: 293
Study 9102059 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU intranasal calcitonin daily
Number of subjects: 123
Study 9102059 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 intramuscular injections of 50 mg nandrolone decanoate plus placebo nasal spray
Number of subjects: 123
Study 9102059 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 123
Study 9102059 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 injections of 50 mg nandrolone decanoate plus 400 IU intranasal calcitonin daily
Number of subjects: 123
Study 9102059 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate
Number of subjects: 123
Study 9102059 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin
Number of subjects: 123
Study 9102059 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate and intranasal calcitonin
Number of subjects: 123
Study 8110036 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumatic spacer device
Number of subjects: 18
Study 8110036 — intervention group
Group type: COMPARATOR
Intervention: Corniced extension tube
Number of subjects: 18
Study 2871785 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevantolol
Number of subjects: 0
Study 2871785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31928372 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern matching method for identifying advanced cancer patients
Number of subjects: 586
Study 31928372 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD-10 algorithm for identifying advanced cancer patients
Number of subjects: 586
Study 31928372 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined ICD-10 algorithm excluding hematological malignancies
Number of subjects: 586
Study 29520735 — intervention group
Group type: EXPERIMENTAL
Intervention: ART (IVF and ICSI)
Number of subjects: 460
Study 29520735 — intervention group
Group type: COMPARATOR
Intervention: non-ART (IUI and OI)
Number of subjects: 460
Study 26608279 — intervention group
Group type: EXPERIMENTAL
Intervention: SET with values affirmation
Number of subjects: 32
Study 26608279 — intervention group
Group type: EXPERIMENTAL
Intervention: SET
Number of subjects: 32
Study 26608279 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study 24420765 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory (WM) training program
Number of subjects: 62
Study 24420765 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 62
Study 22289649 — intervention group
Group type: EXPERIMENTAL
Intervention: Menaquinone-7 (MK-7) supplementation at doses around RDA (10, 20, 45, 90, 180, or 360 μg)
Number of subjects: 42
Study 22289649 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 42
Study 20833391 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adhesive mesh (Parietene Progrip(®))
Number of subjects: 90
Study 20833391 — intervention group
Group type: COMPARATOR
Intervention: Polypropylene mesh fixed with a monofilament suture
Number of subjects: 90
Study 19134299 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic root dimension (ARD) measurement in ACI patients
Number of subjects: 110
Study 19134299 — intervention group
Group type: COMPARATOR
Intervention: Control group without cerebral infarction or organic heart disease
Number of subjects: 110
Study 19134299 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ARD between ACI patients and control subjects
Number of subjects: 110
Study 19134299 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis of ARD as a risk factor for ACI
Number of subjects: 110
Study 15926290 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 33
Study 15926290 — intervention group
Group type: COMPARATOR
Intervention: Formocresol (FC)
Number of subjects: 33
Study 12663728 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco Intervention (TI) group received intensive late effects risk counseling, educational video, goal setting, written physician feedback, smoking literature, and follow-up telephone counseling.
Number of subjects: 103
Study 12663728 — intervention group
Group type: COMPARATOR
Intervention: Standard Care Control (SCC) group received standard advice about the risks of tobacco use.
Number of subjects: 103
Study 11097130 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion therapy
Number of subjects: 1430
Study 11097130 — intervention group
Group type: COMPARATOR
Intervention: No reperfusion therapy
Number of subjects: 1430
Study 8644836 — intervention group
Group type: EXPERIMENTAL
Intervention: Pet therapy intervention for 1 hr a day for 5 consecutive days
Number of subjects: 58
Study 8644836 — intervention group
Group type: COMPARATOR
Intervention: Exercise control for 1 hr a day for 5 consecutive days
Number of subjects: 58
Study 1996747 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/Ketamine combination
Number of subjects: 18
Study 1996747 — intervention group
Group type: COMPARATOR
Intervention: Propofol/Fentanyl combination
Number of subjects: 18
Study 6825409 — intervention group
Group type: EXPERIMENTAL
Intervention: High animal protein diet (HPD)
Number of subjects: 8
Study 6825409 — intervention group
Group type: COMPARATOR
Intervention: Low animal protein diet (LPD)
Number of subjects: 8
Study 31791285 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile enhanced Family Integrated Care (mFICare)
Number of subjects: 0
Study 31791285 — intervention group
Group type: COMPARATOR
Intervention: Usual Family Centered Care (FCC)
Number of subjects: 0
Study 27920258 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 280
Study 27920258 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Continuous Training (HICT)
Number of subjects: 280
Study 27920258 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 280
Study 27920258 — intervention group
Group type: COMPARATOR
Intervention: Non-Exercise Control (NON-EX)
Number of subjects: 280
Study 26674907 — intervention group
Group type: EXPERIMENTAL
Intervention: Eggshell-derived hydroxyapatite (EHA)
Number of subjects: 20
Study 26674907 — intervention group
Group type: COMPARATOR
Intervention: Synthetic hydroxyapatite (SHA)
Number of subjects: 20
Study 24279638 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary treatment (12 sessions for 6 weeks)
Number of subjects: 153
Study 24279638 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care pharmacologic treatment
Number of subjects: 153
Study 23010556 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (n=586)
Number of subjects: 1180
Study 23010556 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=594)
Number of subjects: 1180
Study 18795255 — intervention group
Group type: EXPERIMENTAL
Intervention: AVAPS therapy
Number of subjects: 28
Study 18795255 — intervention group
Group type: COMPARATOR
Intervention: NIV-PS therapy
Number of subjects: 28
Study 18795255 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 28
Study 18795255 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral decubitus position
Number of subjects: 28
Study 17113635 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE bond with 10 s air drying
Number of subjects: 10
Study 17113635 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Tri-S bond with 10 s air drying
Number of subjects: 10
Study 17113635 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE bond with 2 s air drying
Number of subjects: 10
Study 17113635 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Tri-S bond with 2 s air drying
Number of subjects: 10
Study 15088288 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg daily by injection
Number of subjects: 1399
Study 15088288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1399
Study 11699675 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal-based model
Number of subjects: 104
Study 11699675 — intervention group
Group type: EXPERIMENTAL
Intervention: Biology-based model
Number of subjects: 104
Study 11699675 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological capacities attribution
Number of subjects: 104
Study 11699675 — intervention group
Group type: EXPERIMENTAL
Intervention: Finalist model
Number of subjects: 104
Study 11699675 — intervention group
Group type: EXPERIMENTAL
Intervention: Complexity-based teleology
Number of subjects: 104
Study 9554521 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) modulated by 6S‐leucovorin (6S‐LV)
Number of subjects: 72
Study 9554521 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin, etoposide, cisplatin, and lonidamine (EEP‐L)
Number of subjects: 72
Study 9554521 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (5‐FU/6S‐LV and EEP‐L)
Number of subjects: 72
Study 9554521 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU/6S‐LV
Number of subjects: 72
Study 9554521 — intervention group
Group type: EXPERIMENTAL
Intervention: EEP‐L
Number of subjects: 72
Study 8155091 — intervention group
Group type: EXPERIMENTAL
Intervention: AHA type diet 32/10:8:8
Number of subjects: 160
Study 8155091 — intervention group
Group type: EXPERIMENTAL
Intervention: monoene‐enriched diet 34/11:11:5
Number of subjects: 160
Study 8155091 — intervention group
Group type: COMPARATOR
Intervention: reduced‐fat diet 30/12:8:3
Number of subjects: 160
Study 8155091 — intervention group
Group type: COMPARATOR
Intervention: control diet 35/14:10:4
Number of subjects: 160
Study 3046542 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal clonidine hydrochloride (Catapres‐TTS No. 2) treatment for one week
Number of subjects: 40
Study 3046542 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40
Study 28700515 — intervention group
Group type: EXPERIMENTAL
Intervention: TR1: 3 × 10 [0 seconds]
Number of subjects: 11
Study 28700515 — intervention group
Group type: EXPERIMENTAL
Intervention: CL2: 3 × 10 [15 seconds]
Number of subjects: 11
Study 28700515 — intervention group
Group type: EXPERIMENTAL
Intervention: CL3: 3 × 10 [30 seconds]
Number of subjects: 11
Study 28700515 — intervention group
Group type: EXPERIMENTAL
Intervention: TR2: 6 × 5 [0 seconds]
Number of subjects: 11
Study 28700515 — intervention group
Group type: EXPERIMENTAL
Intervention: CL1: 3 × 10 [10 seconds]
Number of subjects: 11
Study 28700515 — intervention group
Group type: EXPERIMENTAL
Intervention: CL4: 1 × 30 [15 seconds]
Number of subjects: 11
Study 30641885 — intervention group
Group type: EXPERIMENTAL
Intervention: No-anesthesia (RIPC)
Number of subjects: 61
Study 30641885 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (RIPC)
Number of subjects: 61
Study 30641885 — intervention group
Group type: COMPARATOR
Intervention: Propofol (RIPC)
Number of subjects: 61
Study 30641885 — intervention group
Group type: EXPERIMENTAL
Intervention: No carvedilol (RIPC)
Number of subjects: 61
Study 30641885 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol (RIPC)
Number of subjects: 61
Study 28789681 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness
Number of subjects: 189
Study 28789681 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin
Number of subjects: 189
Study 28789681 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 189
Study 25403343 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral topiramate (TPM)
Number of subjects: 100
Study 25403343 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous topiramate (TPM)
Number of subjects: 100
Study 25403343 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM) 100 mg dose
Number of subjects: 100
Study 24041732 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Based Antenatal Care (GBAC)
Number of subjects: 700
Study 24041732 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 700
Study 21565325 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured exercise training plus usual care
Number of subjects: 2331
Study 21565325 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2331
Study 19096005 — intervention group
Group type: EXPERIMENTAL
Intervention: A allele of promoter SNP rs2241712
Number of subjects: 881
Study 19096005 — intervention group
Group type: EXPERIMENTAL
Intervention: C allele of SNP rs1800469
Number of subjects: 881
Study 19096005 — intervention group
Group type: EXPERIMENTAL
Intervention: C allele of exonic SNP rs1800471
Number of subjects: 881
Study 19096005 — intervention group
Group type: EXPERIMENTAL
Intervention: T allele of coding SNP rs1982073
Number of subjects: 881
Study 17008336 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education-exercise group (n=97)
Number of subjects: 183